The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?

EGFR tyrosine kinase inhibitors (TKI) have shown the efficacy in treatment of lung cancer patients with EGFR sensitizing mutations, and their use has led to a doubling of progression-free survival (PFS) and a lengthening of overall survival (OS) by more than 2 years.